Evolving gene therapy approaches for osteosarcoma using viral vectors: Review

Bone

Volumn 40, Issue 4, 2007, Pages 797-812

  Witlox, M A ^a   Lamfers, M L ^a   Wuisman, P I J M ^a   Curiel, D T ^b   Siegal, G P ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b and Clinical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Gene therapy; Osteosarcoma; Virus

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CARBOXYLESTERASE; CISPLATIN; DOXORUBICIN; GANCICLOVIR; HERPESVIRUS VECTOR; INTERLEUKIN 12; IRINOTECAN; LENTIVIRUS VECTOR; LIPOSOME; METHOTREXATE; ONYX 015; PARVOVIRUS VECTOR; PLASMID DNA; POLYMER; PRODRUG; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; THYMIDINE KINASE; VIRUS VECTOR;

ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; IN VIVO GENE TRANSFER; LUNG METASTASIS; NONHUMAN; OSTEOSARCOMA; REVIEW; SUICIDE GENE THERAPY; SYSTEMATIC REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

BONE NEOPLASMS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MUTATION; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; SAFETY; VIRUSES;

EID: 33947174799     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.10.017     Document Type: Review

References (162)

1. Abbott A. Questions linger about unexplained gene-therapy trial death. Nat. Med. 12 (2006) 597
2. Adachi Y., Reynolds P.N., Yamamoto M., Wang M., Takayama K., Matsubara S., et al. A midline promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res. 61 (2001) 7882-7888
3. Arkin L.M., Sondhi D., Worgall S., Suh L.H., Hackett N.R., Kaminsky S.M., et al. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther. 16 (2005) 1028-1036
4. Bacci G., Briccoli A., Rocca M., Ferrari S., Donati D., Longhi A., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann. Oncol. 14 (2003) 1126-1134
5. Barnett B.G., Tillman B.W., Curiel D.T., and Douglas J.T. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol. Ther. 6 (2002) 377-385
6. Benassi M.S., Molendini L., Gamberi G., Sollazzo M.R., Ragazzini P., Merli M., et al. Altered G1 phase regulation in osteosarcoma. Int. J. Cancer 74 (1997) 518-522
7. Benjamin R., Helman L., Meyers P., and Reaman G. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum. Gene Ther. 12 (2001) 1591-1593
8. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997) 1320-1323
9. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
10. Blackwell J.L., Miller C.R., Douglas J.T., Li H., Reynolds P.N., Carroll W.R., et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol., Head Neck Surg. 125 (1999) 856-863
11. Bloom D. Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity. AMA Am. J. Dis. Child. 88 (1954) 754-758
12. Bonnet M.C., Tartaglia J., Verdier F., Kourilsky P., Lindberg A., Klein M., et al. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol. Lett. 74 (2000) 11-25
13. Bowers W.J., Olschowka J.A., and Federoff H.J. Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther. 10 (2003) 941-945
14. Brown B.D., and Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood 100 (2002) 1133-1140
15. Charissoux J.L., Grossin L., Leboutet M.J., and Rigaud M. Treatment of experimental osteosarcoma tumors in rat by herpes simplex thymidine kinase gene transfer and ganciclovir. Anticancer Res. 19 (1999) 77-80
16. Chen D., Murphy B., Sung R., and Bromberg J.S. Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function. Gene Ther. 10 (2003) 991-998
17. Cheon J., Kim H.K., Moon D.G., Yoon D.K., Cho J.H., and Koh S.K. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. BJU Int. 85 (2000) 759-766
18. Cheon J., Ko S.C., Gardner T.A., Shirakawa T., Gotoh A., Kao C., et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4 (1997) 359-365
19. Chi S.N., Conklin L.S., Qin J., Meyers P.A., Huvos A.G., Healey J.H., et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr. Blood Cancer 42 (2004) 46-51
20. Chuah M.K., Collen D., and Vanden Driessche T. Biosafety of adenoviral vectors. Curr. Gene Ther. 3 (2003) 527-543
21. Conrad C., Miller C.R., Ji Y., Gomez-Manzano C., Bharara S., McMurray J.S., et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 12 (2005) 284-294
22. Craig C., Kim M., Ohri E., Wersto R., Katayose D., Li Z., et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 16 (1998) 265-272
23. Cripe T.P., Dunphy E.J., Holub A.D., Saini A., Vasi N.H., Mahller Y.Y., et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 61 (2001) 2953-2960
24. Crystal R.G. Transfer of genes to humans: early lessons and obstacles to success. Science 270 (1995) 404-410
25. Densmore C.L., Kleinerman E.S., Gautam A., Jia S.F., Xu B., Worth L.L., et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8 (2001) 619-627
26. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61 (2001) 7464-7472
27. Dirven C.M., Grill J., Lamfers M.L., Van der Valk P., Leonhart A.M., Van Beusechem V.W., et al. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J. Neurosurg. 97 (2002) 441-449
28. Dmitriev I., Kashentseva E., Rogers B.E., Krasnykh V., and Curiel D.T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74 (2000) 6875-6884
29. Dorfman, HD, Czemiak, B, Bone tumors. St. Louis: Mosby; 1997.
30. Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., and Curiel D.T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14 (1996) 1574-1578
31. Everts M., and Curiel D.T. Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4 (2004) 337-346
32. Ferrari S., Bacci G., Picci P., Mercuri M., Briccoli A., Pinto D., et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann. Oncol. 8 (1997) 765-771
33. Feugeas O., Guriec N., Babin-Boilletot A., Marcellin L., Simon P., Babin S., et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J. Clin. Oncol. 14 (1996) 467-472
34. Fischer A. Gene therapy: some results, many problems to solve. Cell. Mol. Biol. (Noisy-le-Grand) 47 (2001) 1269-1275
35. Florenes V.A., Maelandsmo G.M., Forus A., Andreassen A., Myklebost O., and Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst. 86 (1994) 1297-1302
36. Frolkis M., Fischer M.B., Wang Z., Lebkowski J.S., Chiu C.P., and Majumdar A.S. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther. 10 (2003) 239-249
37. Fuchs N., and Winkler K. Osteosarcoma. Curr. Opin Oncol. 5 (1993) 667-671
38. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonnell T.J., Mitlianga P., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19 (2000) 2-12
39. Gallardo D., Drazan K.E., and McBride W.H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 56 (1996) 4891-4893
40. Ganjavi H., Gee M., Narendran A., Parkinson N., Krishnamoorthy M., Freedman M.H., et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. (2005)
41. Geoerger B., Grill J., Opolon P., Morizet J., Aubert G., Terrier-Lacombe M.J., et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62 (2002) 764-772
42. Geoerger B., Vassal G., Opolon P., Dirven C.M., Morizet J., Laudani L., et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res. 64 (2004) 5753-5759
43. Glasgow J.N., Kremer E.J., Hemminki A., Siegal G.P., Douglas J.T., and Curiel D.T. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 324 (2004) 103-116
44. Graat H.C., Wuisman P.I., van Beusechem V.W., Carette J.E., Gerritsen W.R., Bras J., et al. Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses. Clin. Cancer Res. 11 (2005) 2445-2447 [author reply 2447-8; 2005]
45. Grez M. [Gene therapy was declared a success. However, one patient was already dead]. MMW Fortschr. Med. 148 (2006) 16
46. Grill J., Van Beusechem V.W., Van Der Valk P., Dirven C.M., Leonhart A., Pherai D.S., et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7 (2001) 641-650
47. Gu Z., Kuntz-Simon G., Rommelaere J., and Cornelis J. Oncogenic transformation-dependent expression of a transcription factor NF-Y subunit. Mol. Carcinog. 24 (1999) 294-299
48. Guo W., Wang X., and Feng C. P53 gene abnormalities in osteosarcoma. Chin Med. J. (Engl.) 109 (1996) 752-755
49. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348 (2003) 255-256
50. Haisma H.J., Grill J., Curiel D.T., Hoogeland S., van Beusechem V.W., Pinedo H.M., et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 7 (2000) 901-904
51. Hansen M.F., Koufos A., Gallie B.L., Phillips R.A., Fodstad O., Brogger A., et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc. Natl. Acad Sci. U. S. A. 82 (1985) 6216-6220
52. Harris M.P., Sutjipto S., Wills K.N., Hancock W., Cornell D., Johnson D.E., et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 3 (1996) 121-130
53. Harvey B.G., Worgall S., Ely S., Leopold P.L., and Crystal R.G. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector. Hum. Gene Ther. 10 (1999) 2823-2837
54. Haviv Y.S., and Curiel D.T. Conditional gene targeting for cancer gene therapy. Adv. Drug Delivery Rev. 53 (2001) 135-154
55. Heise C., Ganly I., Kim Y.T., Sampson-Johannes A., Brown R., and Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 7 (2000) 1925-1929
56. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., and Kirn D.H. ONYX-015 an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3 (1997) 639-645
57. Heise C.C., Williams A.M., Xue S., Propst M., and Kirn D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59 (1999) 2623-2628
58. Hellwinkel O.J., Muller J., Pollmann A., and Kabisch H. Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J. Gene Med. 7 (2005) 407-419
59. Hemminki A., Kanerva A., Kremer E.J., Bauerschmitz G.J., Smith B.F., Liu B., et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 7 (2003) 163-173
60. Henry L.J., Xia D., Wilke M.E., Deisenhofer J., and Gerard R.D. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J. Virol. 68 (1994) 5239-5246
61. Hermens W.T., and Verhaagen J. Viral vectors, tools for gene transfer in the nervous system. Prog. Neurobiol. 55 (1998) 399-432
62. Huber B.E., Austin E.A., Good S.S., Knick V.C., Tibbels S., and Richards C.A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53 (1993) 4619-4626
63. Huvos A.G. Bone tumors. Diagnosis, treatment and prognosis. Philedelphia (1991)
64. Jia S.F., Worth L.L., Densmore C.L., Xu B., Zhou Z., and Kleinerman E.S. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 9 (2002) 260-266
65. Jia S.F., Worth L.L., and Kleinerman E.S. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis 17 (1999) 501-506
66. Kanai F., Lan K.H., Shiratori Y., Tanaka T., Ohashi M., Okudaira T., et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 57 (1997) 461-465
67. Ketola A., Maatta A.M., Pasanen T., Tulimaki K., and Wahlfors J. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy. Int. J. Mol. Med. 13 (2004) 705-710
68. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 (2000) 879-885
69. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin Oncol. 13 (2001) 506-513
70. Klein M.J., and Siegal G.P. Osteosarcoma: anatomic and histologic variants. Am. J. Clin Pathol. 125 (2006) 555-581
71. Koeneman K.S., Kao C., Ko S.C., Yang L., Wada Y., Kallmes D.F., et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18 (2000) 102-110
72. Kojima A., Hackett N.R., and Crystal R.G. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res. 58 (1998) 4368-4374
73. Krasnykh V., Dmitriev I., Mikheeva G., Miller C.R., Belousova N., and Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 72 (1998) 1844-1852
74. Kuznetsov Y.G., Victoria J.G., Low A., Robinson Jr. W.E., Fan H., and McPherson A. Atomic force microscopy imaging of retroviruses: human immunodeficiency virus and murine leukemia virus. Scanning 26 (2004) 209-216
75. Kuznetsov Y.G., Victoria J.G., Robinson Jr. W.E., and McPherson A. Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-infected lymphocytes. J. Virol. 77 (2003) 11896-11909
76. Lafleur E.A., Jia S.F., Worth L.L., Zhou Z., Owen-Schaub L.B., and Kleinerman E.S. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 61 (2001) 4066-4071
77. Lamfers M.L., Gianni D., Tung C.H., Idema S., Schagen F.H., Carette J.E., et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res. 65 (2005) 9398-9405
78. Lamfers M.L., Grill J., Dirven C.M., Van Beusechem V.W., Geoerger B., Van Den Berg J., et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 62 (2002) 5736-5742
79. Lamont J.P., Nemunaitis J., Kuhn J.A., Landers S.A., and McCarty T.M. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7 (2000) 588-592
80. Laube B.L. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir. Care 50 (2005) 1161-1176
81. Le L.P., Li J., Ternovoi V.V., Siegal G.P., and Curiel D.T. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J. Gen. Virol. 86 (2005) 3201-3208
82. Le L.P., Rivera A.A., Glasgow J.N., Ternovoi V.V., Wu H., Wang M., et al. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 13 (2006) 389-399
83. Li F.P., Fraumeni Jr. J.F., Mulvihill J.J., Blattner W.A., Dreyfus M.G., Tucker M.A., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48 (1988) 5358-5362
84. Li X., Jung C., Liu Y.H., Bae K.H., Zhang Y.P., Zhang H.J., et al. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. J. Gene Med. 8 (2006) 679-689
85. Li Y., Pong R.C., Bergelson J.M., Hall M.C., Sagalowsky A.I., Tseng C.P., et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59 (1999) 325-330
86. Li Y., Yu D.C., Chen Y., Amin P., Zhang H., Nguyen N., et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 61 (2001) 6428-6436
87. Liebau C., Merk H., Schmidt S., Roesel C., Karreman C., Prisack J.B., et al. Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol. Ther. 7 (2002) 135-142
88. Liebau C., Roesel C., Schmidt S., Karreman C., Prisack J.B., Bojar H., et al. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res. 24 (2004) 2861-2867
89. Lindner N.J., Ramm O., Hillmann A., Roedl R., Gosheger G., Brinkschmidt C., et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop. (1999) 83-89
90. Link M.P., Goorin A.M., Horowitz M., Meyer W.H., Belasco J., Baker A., et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. (1991) 8-14
91. Lonardo F., Ueda T., Huvos A.G., Healey J., and Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79 (1997) 1541-1547
92. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 21 (2003) 117-122
93. Marcove R.C., Heelan R.T., Huvos A.G., Healey J., and Lindeque B.G. Osteoid osteoma. Diagnosis, localization, and treatment. Clin. Orthop. (1991) 197-201
94. Masuda H., Miller C., Koeffler H.P., Battifora H., and Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad Sci. U. S. A. 84 (1987) 7716-7719
95. Matsubara S., Wada Y., Gardner T.A., Egawa M., Park M.S., Hsieh C.L., et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 61 (2001) 6012-6019
96. Mehrara B.J., Saadeh P.B., Steinbrech D.S., Dudziak M., Spector J.A., Greenwald J.A., et al. Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. J. Bone Miner. Res. 14 (1999) 1290-1301
97. Meyers P.A., Gorlick R., Heller G., Casper E., Lane J., Huvos A.G., et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J. Clin. Oncol. 16 (1998) 2452-2458
98. Miller C.W., Aslo A., Tsay C., Slamon D., Ishizaki K., Toguchida J., et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50 (1990) 7950-7954
99. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., and Koeffler H.P. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol. 122 (1996) 559-565
100. Mori K., Redini F., Gouin F., Cherrier B., and Heymann D. Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol. Rep. 15 (2006) 693-700
101. Mullen C.A., Coale M.M., Lowe R., and Blaese R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54 (1994) 1503-1506
102. Nakase M., Inui M., Okumura K., Kamei T., Nakamura S., and Tagawa T. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol. Cancer Ther. 4 (2005) 625-631
103. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19 (2001) 289-298
104. Nencioni A., Muller M.R., Grunebach F., Garuti A., Mingari M.C., Patrone F., et al. Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther. 10 (2003) 209-214
105. Nettelbeck D.M., Rivera A.A., Balague C., Alemany R., and Curiel D.T. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62 (2002) 4663-4670
106. Nielsen L.L., Dell J., Maxwell E., Armstrong L., Maneval D., and Catino J.J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4 (1997) 129-138
107. Nielsen L.L., and Maneval D.C. P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 5 (1998) 52-63
108. Ohwada A., Hirschowitz E.A., and Crystal R.G. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum. Gene Ther. 7 (1996) 1567-1576
109. Ono H.A., Davydova J.G., Adachi Y., Takayama K., Barker S.D., Reynolds P.N., et al. Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer. J. Gastroenterol. 40 (2005) 31-42
110. Oosterhoff D., Pinedo H.M., van der Meulen I.H., de Graaf M., Sone T., Kruyt F.A., et al. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br. J. Cancer 87 (2002) 659-664
111. Oosterhoff D., Pinedo H.M., Witlox M.A., Carette J.E., Gerritsen W.R., and van Beusechem V.W. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther. 12 (2005) 1011-1018
112. Oosterhoff D., Witlox M.A., van Beusechem V.W., Haisma H.J., Schaap G.R., Bras J., et al. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol. Cancer Ther. 2 (2003) 765-771
113. Patil S.D., Rhodes D.G., and Burgess D.J. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 7 (2005) E61-E77
114. Phelan A., Elliott G., and O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16 (1998) 440-443
115. Pollmann A., Kabisch H., Block A., Muller J., and Hellwinkel O.J. Limited specificity of promoter constructs for gene therapy in osteosarcoma. Int. J. Mol. Med. 14 (2004) 737-742
116. Portella G., Scala S., Vitagliano D., Vecchio G., and Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 87 (2002) 2525-2531
117. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11 (2000) 2389-2401
118. Ramnaraine M., Pan W., and Clohisy D.R. Osteoclasts direct bystander killing of cancer cells in vitro. Bone 38 (2006) 4-12
119. Ramnaraine M., Pan W., Goblirsch M., Lynch C., Lewis V., Orchard P., et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res. 63 (2003) 6847-6854
120. Rancourt C., Rogers B.E., Sosnowski B.A., Wang M., Piche A., Pierce G.F., et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4 (1998) 2455-2461
121. Reid T., Galanis E., Abbruzzese J., Sze D., Andrews J., Romel L., et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8 (2001) 1618-1626
122. Reid T., Warren R., and Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9 (2002) 979-986
123. Renard A.J., Veth R.P., Schreuder H.W., Pruszczynski M., Bokkerink J.P., van Hoesel Q.G., et al. Osteosarcoma: oncologic and functional results. A single institutional report covering 22 years. J. Surg. Oncol. 72 (1999) 124-129
124. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., and Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57 (1997) 2559-2563
125. Rosenfeld M.E., Feng M., Michael S.I., Siegal G.P., Alvarez R.D., and Curiel D.T. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin. Cancer Res. 1 (1995) 1571-1580
126. Roth J.A., and Cristiano R.J. Gene therapy for cancer: what have we done and where are we going?. J. Natl. Cancer Inst. 89 (1997) 21-39
127. Rothmund A. Ueber katarakt in verbindiung mit einer eigentuemlichen haut degeneration. Arch. f. Ophth. 14 (1868) 159-182
128. Sanders R.P., Drissi R., Billups C.A., Daw N.C., Valentine M.B., and Dome J.S. Telomerase expression predicts unfavorable outcome in osteosarcoma. J. Clin Oncol. 22 (2004) 3790-3797
129. Satoh T., and Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 257-288
130. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol. Ther. 4 (2005) 512-517
131. Shirakawa T., Ko S.C., Gardner T.A., Cheon J., Miyamoto T., Gotoh A., et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 5 (1998) 274-280
132. Siders W.M., Halloran P.J., and Fenton R.G. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56 (1996) 5638-5646
133. Sluga M., Windhager R., Lang S., Heinzl H., Bielack S., and Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin. Orthop. (1999) 120-127
134. Song S.U., and Boyce F.M. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp. Mol. Med. 33 (2001) 46-53
135. Stefani A.L., Barzon L., Castagliuolo I., Guido M., Pacenti M., Parolin C., et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 42 (2005) 728-735
136. Stoff-Khalili M.A., Rivera A.A., Glasgow J.N., Le L.P., Stoff A., Everts M., et al. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 12 (2005) 1696-1706
137. Strauss S.J., McTiernan A., and Whelan J.S. Late relapse of osteosarcoma: implications for follow-up and screening. Pediatr. Blood Cancer 43 (2004) 692-697
138. Ternovoi V.V., Le L.P., Belousova N., Smith B.F., Siegal G.P., and Curiel D.T. Productive replication of human adenovirus type 5 in canine cells. J. Virol. 79 (2005) 1308-1311
139. Thomson M. A hitherto undescribed familial disease. Br. J. Dermatol. 135 (1923)
140. Tsuchiya H., Mori Y., Ueda Y., Okada G., and Tomita K. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 20 (2000) 235-242
141. Tsuji H., Kawaguchi S., Wada T., Nagoya S., Inobe M., Yagita H., et al. Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer. Cancer Gene Ther. 10 (2003) 717-725
142. Tsuji H., Kawaguchi S., Wada T., Nagoya S., Inobe M., Yamashita T., et al. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 9 (2002) 747-755
143. Uchino J., Takayama K., Harada A., Kawakami Y., Inoue H., Curiel D.T., et al. Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. Cancer Gene Ther. 12 (2005) 737-748
144. Unni, KK: General Aspects and data on 11,087 cases. Dahlin's Bone Tumors, pp. 143-183. Philadelphia: Lippincott-raven; 1996.
145. van Beusechem V.W., van den Doel P.B., Grill J., Pinedo H.M., and Gerritsen W.R. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62 (2002) 6165-6171
146. van der Poel H.G., Molenaar B., van Beusechem V.W., Haisma H.J., Rodriguez R., Curiel D.T., et al. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. J. Urol. 168 (2002) 266-272
147. Vasey P.A., Shulman L.N., Campos S., Davis J., Gore M., Johnston S., et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20 (2002) 1562-1569
148. Wang Y., and Yuan F. Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Ann. Biomed. Eng. 34 (2006) 114-127
149. Wesseling J.G., Bosma P.J., Krasnykh V., Kashentseva E.A., Blackwell J.L., Reynolds P.N., et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 8 (2001) 969-976
150. Wickham T.J., Mathias P., Cheresh D.A., and Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 (1993) 309-319
151. Wierdl M., Morton C.L., Weeks J.K., Danks M.K., Harris L.C., and Potter P.M. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 61 (2001) 5078-5082
152. Wildner O., Blaese R.M., and Morris J.C. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 59 (1999) 410-413
153. Witlox A.M., Van Beusechem V.W., Molenaar B., Bras H., Schaap G.R., Alemany R., et al. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin. Cancer Res. 10 (2004) 61-67
154. Witlox M.A., Van Beusechem V.W., Grill J., Haisma H.J., Schaap G., Bras J., et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 4 (2002) 510-516
155. Worth L.L., Jia S.F., Zhou Z., Chen L., and Kleinerman E.S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. 6 (2000) 3713-3718
156. Xia C.Q., Wang J., and Shen W.C. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 295 (2000) 594-600
157. Xu H.J., Zhou Y., Seigne J., Perng G.S., Mixon M., Zhang C., et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56 (1996) 2245-2249
158. Xu X.L., Tang T., Dai K., Zhu Z., Guo X.E., Yu C., et al. Immune response and effect of adenovirus-mediated human BMP-2 gene transfer on the repair of segmental tibial bone defects in goats. Acta Orthop. 76 (2005) 637-646
159. Yamamoto M., Davydova J., Wang M., Siegal G.P., Krasnykh V., Vickers S.M., et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125 (2003) 1203-1218
160. Yamamura H., Hashio M., Noguchi M., Sugenoya Y., Osakada M., Hirano N., et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 61 (2001) 3969-3977
161. You L., Yang C.T., and Jablons D.M. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60 (2000) 1009-1013
162. Zhu W., Rawlins B.A., Boachie-Adjei O., Myers E.R., Arimizu J., Choi E., et al. Combined bone morphogenetic protein-2 and-7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J. Bone Miner. Res. 19 (2004) 2021-2032